{
 "method": [
  {
   "value": "540",
   "label": "drug CGMP warning letters, Jan 2021 to 10 Nov 2026"
  },
  {
   "value": "233",
   "label": "state the rule for relying on a supplier's results"
  },
  {
   "value": "25 of 25",
   "label": "sampled matches read by hand were the rule"
  },
  {
   "value": "128",
   "label": "quotes checked word for word against the letters"
  }
 ],
 "hint": "Open a row to see the letters behind its count. The highlight marks the words the count rests on.",
 "rows": [
  {
   "id": "two-stage",
   "label": "Asks how the firm will validate supplier results, first and periodically",
   "count": 187,
   "records": [
    {
     "title": "Conroe Welding Supply",
     "meta": [
      "29 October 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "If you intend to accept any results from your supplier’s COA instead of testing each DMG lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation.",
       "tone": "source",
       "mark": [
        158,
        270
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/conroe-welding-supply-inc-731507-10292026",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Pritam International",
     "meta": [
      "27 October 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation.",
       "tone": "source",
       "mark": [
        164,
        276
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pritam-international-private-limited-738079-10272026",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "TSP Solutions",
     "meta": [
      "22 October 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation.",
       "tone": "source",
       "mark": [
        164,
        277
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tsp-solutions-pte-ltd-735071-10222026",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Zhejiang Gaorong Cosmetic",
     "meta": [
      "1 October 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation and periodic revalidation.",
       "tone": "source",
       "mark": [
        164,
        269
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/zhejiang-gaorong-cosmetic-co-ltd-732511-10012026",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "SnugZ USA",
     "meta": [
      "28 September 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation.",
       "tone": "source",
       "mark": [
        164,
        277
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/snugz-usa-inc-735284-09282026",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Jiangmen Shuizirun Sanitary Articles",
     "meta": [
      "23 September 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "If you intend to accept any results from your supplier’s certificates of analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation.",
       "tone": "source",
       "mark": [
        191,
        304
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/jiangmen-shuizirun-sanitary-articles-co-ltd-722974-09232026",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Bentley Laboratories",
     "meta": [
      "17 September 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation.",
       "tone": "source",
       "mark": [
        164,
        277
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bentley-laboratories-llc-732028-09172026",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Happy Farm Botanicals",
     "meta": [
      "1 September 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "If you intend to accept any results from your supplier’s Certificates of Analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation.",
       "tone": "source",
       "mark": [
        191,
        304
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/happy-farm-botanicals-inc-731926-09012026",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Suretec Innovations",
     "meta": [
      "13 August 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation.",
       "tone": "source",
       "mark": [
        164,
        277
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/suretec-innovations-llc-730122-08132026",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Woodbine Products Company",
     "meta": [
      "27 July 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation.",
       "tone": "source",
       "mark": [
        164,
        276
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/woodbine-products-company-inc-729345-07272026",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Thomas Brunner Hygiene",
     "meta": [
      "24 July 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "If you intend to accept any results from your suppliers’ certificates of analysis (COAs) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your suppliers’ results through initial validation and periodic revalidation.",
       "tone": "source",
       "mark": [
        192,
        297
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/thomas-brunner-hygiene-gmbh-729018-07242026",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Spa De Soleil",
     "meta": [
      "8 July 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation.",
       "tone": "source",
       "mark": [
        164,
        276
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/spa-de-soleil-inc-728508-07082026",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Laboratorios Dr. Collado",
     "meta": [
      "2 June 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will establish the reliability of your supplier’s results through initial validation as well as periodic revalidation.",
       "tone": "source",
       "mark": [
        155,
        267
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/laboratorios-dr-collado-sa-723285-06022026",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Revlon Group Holdings",
     "meta": [
      "2 June 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will establish the reliability of your supplier’s results through initial validation as well as periodic revalidation.",
       "tone": "source",
       "mark": [
        155,
        267
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/revlon-group-holdings-llc-722596-06022026",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Erkul Kozmetik Sanayi ve Ticaret A.S",
     "meta": [
      "2 June 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "If you intend to accept any results from your supplier’s Certificates of Analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will establish the reliability of your supplier’s results through initial validation as well as periodic re-validation.",
       "tone": "source",
       "mark": [
        182,
        295
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/erkul-kozmetik-sanayi-ve-ticaret-721964-06022026",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Gopaldas Visram &",
     "meta": [
      "2 June 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "If you intend to accept any results from your supplier’s Certificates of Analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will establish the reliability of your supplier’s results through initial validation as well as periodic re-validation.",
       "tone": "source",
       "mark": [
        182,
        295
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gopaldas-visram-co-ltd-721755-06022026",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Shantou Qiwei Industry Co., LTD",
     "meta": [
      "2 June 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will establish the reliability of your supplier’s results through initial validation as well as periodic revalidation.",
       "tone": "source",
       "mark": [
        155,
        267
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/shantou-qiwei-industry-co-ltd-721753-06022026",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Umendra Life Sciences",
     "meta": [
      "2 June 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will establish the reliability of your supplier’s results through initial validation as well as periodic re-validation.",
       "tone": "source",
       "mark": [
        155,
        268
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/umendra-life-sciences-private-limited-721752-06022026",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "PLZ",
     "meta": [
      "2 June 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will establish the reliability of your supplier’s results through initial validation as well as periodic revalidation.",
       "tone": "source",
       "mark": [
        155,
        267
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/plz-corp-721140-06022026",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Asanuma Corporation - Sagamihara Factory",
     "meta": [
      "2 June 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will establish the reliability of your supplier’s results through initial validation as well as periodic revalidation.",
       "tone": "source",
       "mark": [
        155,
        267
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/asanuma-corporation-721136-sagamihara-factory",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Macau-Union Pharmaceutical",
     "meta": [
      "29 May 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "If you intend to accept any results from your supplier’s COA instead of testing each component batch for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation.",
       "tone": "source",
       "mark": [
        166,
        279
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/macau-union-pharmaceutical-limited-724506-05292026",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "GC America",
     "meta": [
      "14 May 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "If you intend to accept any results from your supplier’s certificates of analysis instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation.",
       "tone": "source",
       "mark": [
        185,
        298
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gc-america-inc-727602-05142026",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Active Cosmetics Manufacturing",
     "meta": [
      "22 April 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation.",
       "tone": "source",
       "mark": [
        164,
        276
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/active-cosmetics-manufacturing-inc-722408-04222026",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Foshan Miwei Cosmetics",
     "meta": [
      "20 April 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation.",
       "tone": "source",
       "mark": [
        164,
        276
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/foshan-miwei-cosmetics-co-ltd-722272-04202026",
     "urlLabel": "FDA's letter"
    }
   ],
   "note": "24 of 187 letters, newest first. The wording repeats letter to letter."
  },
  {
   "id": "reliability",
   "label": "Cites the firm for relying on supplier results never shown reliable",
   "count": 46,
   "records": [
    {
     "title": "Guangdong Bangze Medicine",
     "meta": [
      "26 October 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "You also relied on your suppliers' certificates of analysis (COA) for (b)(4) without demonstrating the reliability of your suppliers' test analyses at appropriate intervals.",
       "tone": "source",
       "mark": [
        85,
        172
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/guangdong-bangze-medicine-co-ltd-734509-10262026",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Silgan Dispensing Systems",
     "meta": [
      "5 October 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "For example, your QU failed to: Validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(2)).",
       "tone": "source",
       "mark": [
        32,
        138
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/silgan-dispensing-systems-734538-10052026",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Babikian Healthcare Products CJSC",
     "meta": [
      "21 September 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) & 211.84(d)(2)).",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/babikian-healthcare-products-cjsc-730513-09212026",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "TCI Co., Ltd BioCosme PABP BRANCH",
     "meta": [
      "2 September 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tci-co-ltd-biocosme-pabp-branch-736888-09022026",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Sante Manufacturing",
     "meta": [
      "5 June 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sante-manufacturing-inc-724931-06052026",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Respilon Production S.R.O",
     "meta": [
      "20 April 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/respilon-production-sro-719705-04202026",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "JW Nutritional",
     "meta": [
      "15 April 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "If you intend to accept any results from your suppliers’ certificates of analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your suppliers’ results through initial validation, as well as periodic revalidation.",
       "tone": "source",
       "mark": [
        191,
        243
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/jw-nutritional-llc-722096-04152026",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Purolea Cosmetics Lab",
     "meta": [
      "2 April 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals.",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/purolea-cosmetics-lab-722591-04022026",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "RC Outsourcing",
     "meta": [
      "20 March 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1), 211.84(d)(2)). 6.",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/rc-outsourcing-llc-722877-03202026",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "GenoGenix",
     "meta": [
      "20 January 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)). 9.",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Foshan Yiying Hygiene Products",
     "meta": [
      "10 October 2025",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/foshan-yiying-hygiene-products-co-ltd-715548-10102025",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "RNA Bio/Pharma, Incorporated",
     "meta": [
      "10 October 2025",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/rna-biopharma-incorporated-713201-10102025",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Kabana Skin Care",
     "meta": [
      "18 July 2025",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kabana-skin-care-llc-710232-07182025",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Nature’s Fusions",
     "meta": [
      "25 June 2025",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/natures-fusions-llc-707024-06252025",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Xtreme Tools International",
     "meta": [
      "25 June 2025",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/xtreme-tools-international-inc-706053-06252025",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Product Society",
     "meta": [
      "8 May 2025",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Also, your firm failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
       "tone": "source",
       "mark": [
        26,
        132
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/product-society-llc-702927-05082025",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Ningbo Riway Industrial",
     "meta": [
      "30 April 2025",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ningbo-riway-industrial-co-ltd-692870-04302025",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Taizhou Jingshang Cosmetics Technology",
     "meta": [
      "2 April 2025",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/taizhou-jingshang-cosmetics-technology-co-ltd-701945-04022025",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "ProRx",
     "meta": [
      "4 March 2025",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prorx-llc-696742-03042025",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Imperial Palace Commodity -Dongguan-",
     "meta": [
      "27 January 2025",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/imperial-palace-commodity-dongguan-co-ltd-692842-01272025",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Nubratori, Inc. dba Nubratori Rx",
     "meta": [
      "22 January 2025",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals.",
       "tone": "source",
       "mark": [
        20,
        126
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nubratori-inc-dba-nubratori-rx-700513-01222025",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "LCC",
     "meta": [
      "21 November 2024",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropri ate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
       "tone": "source",
       "mark": [
        25,
        132
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lcc-ltd-688576-11212024",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Eurosirel S.P.A",
     "meta": [
      "20 November 2024",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eurosirel-spa-690733-11202024",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Zhejiang Uniquality Nursing Products Technology Co., Ltd. dba ZheJiang YouQuan Care Products Technology",
     "meta": [
      "12 November 2024",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/zhejiang-uniquality-nursing-products-technology-co-ltd-dba-zhejiang-youquan-care-products-technology",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Diora Kimya Sanayi ve Ticaret Limited Sirketi",
     "meta": [
      "17 October 2024",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/diora-kimya-sanayi-ve-ticaret-limited-sirketi-688271-10172024",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Hangzhou Glamcos Biotech",
     "meta": [
      "7 October 2024",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hangzhou-glamcos-biotech-co-ltd-692583-10072024",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "EnviroServe Chemicals & Cleaners",
     "meta": [
      "9 September 2024",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) & 211.84(d)(2)).",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/enviroserve-chemicals-cleaners-ltd-674090-09092024",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Diamond Chemical Co",
     "meta": [
      "6 September 2024",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/diamond-chemical-co-inc-687078-09062024",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Clean Solutions",
     "meta": [
      "6 September 2024",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/clean-solutions-llc-686995-09062024",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Cosmetic Solutions",
     "meta": [
      "31 May 2024",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "You failed to establish the reliability of your component suppliers’ test analyses at appropriate intervals.",
       "tone": "source",
       "mark": [
        14,
        107
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cosmetic-solutions-llc-670486-05312024",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Seatex",
     "meta": [
      "1 April 2024",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/seatex-llc-672951-04012024-0",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Bodywell Natural Skin Care",
     "meta": [
      "27 March 2024",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Yo ur firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 21 CFR 211.84(d)(2)).",
       "tone": "source",
       "mark": [
        26,
        132
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bodywell-natural-skin-care-inc-677099-03272024",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Omeza",
     "meta": [
      "12 December 2023",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/omeza-llc-665762-12122023",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Handock Cosmetics",
     "meta": [
      "4 October 2023",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 21 CFR 211.84(d)(2)).",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/handock-cosmetics-co-ltd-658737-10042023",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "PureChemPros",
     "meta": [
      "1 September 2023",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/purechempros-llc-649677-09012023",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Avlon Industries",
     "meta": [
      "18 July 2023",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/avlon-industries-inc-652903-07182023",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "LXR Biotech",
     "meta": [
      "17 July 2023",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lxr-biotech-llc-652756-07172023",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Drivergent",
     "meta": [
      "1 May 2023",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/drivergent-inc-647234-05012023",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Pharmedica USA",
     "meta": [
      "28 April 2023",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pharmedica-usa-llc-648269-04282023",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Frenda",
     "meta": [
      "15 February 2023",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/frenda-corporation-642267-02152023",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Auto-Chlor System",
     "meta": [
      "20 December 2022",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/auto-chlor-system-llc-641808-12202022",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Omega & Delta Co",
     "meta": [
      "2 November 2022",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/omega-delta-co-inc-636606-11022022",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "American Cleaning Solutions",
     "meta": [
      "6 September 2022",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and (2)).",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/american-cleaning-solutions-632881-09062022",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Sanitizer Supply",
     "meta": [
      "2 September 2022",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and (2)).",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sanitizer-supply-llc-633583-09022022",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "BioLyte Laboratories",
     "meta": [
      "18 March 2021",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and (2)).",
       "tone": "source",
       "mark": [
        25,
        131
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/biolyte-laboratories-llc-603584-03182021",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Honest Globe",
     "meta": [
      "15 March 2021",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Establish procedures describing critical oversight responsibilities including, but not limited to, the following: batch review and release, developing and assessing corrective and preventive actions, implementing change controls, and establishing the reliability of component supplier analyses.",
       "tone": "source",
       "mark": [
        234,
        293
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/honest-globe-inc-597177-03152021",
     "urlLabel": "FDA's letter"
    }
   ],
   "note": "46 letters, newest first. Most cite 21 CFR 211.84(d)(2)."
  },
  {
   "id": "computer",
   "label": "Cites 21 CFR 211.68(b), controls over computer systems",
   "count": 34,
   "records": [
    {
     "title": "Laboratorios Jaloma S.A. de C.V",
     "meta": [
      "22 May 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).",
       "tone": "source",
       "mark": [
        98,
        141
       ]
      },
      {
       "label": "FDA, next sentence",
       "text": "Your firm lacked sufficient controls over your gas chromatography (GC) instrument used to test components in your finished drug products.",
       "tone": "context"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/laboratorios-jaloma-sa-de-cv-725939-05222026",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "GC America",
     "meta": [
      "14 May 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "The lack of proper electronic record controls undermines the reliability and integrity of your laboratory data (21 CFR 211.68(b)).",
       "tone": "source",
       "mark": [
        19,
        45
       ]
      },
      {
       "label": "FDA, next sentence",
       "text": "Your QU also failed to perform annual product reviews of your drug products since our previous inspection in 2018.",
       "tone": "context"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gc-america-inc-727602-05142026",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Ava",
     "meta": [
      "14 April 2026",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).",
       "tone": "source",
       "mark": [
        98,
        141
       ]
      },
      {
       "label": "FDA, next sentence",
       "text": "Your firm lacked adequate system security and access controls over your laboratory equipment used to test drug products prior to release.",
       "tone": "context"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ava-inc-721180-04142026",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "CDL Services, Inc. DBA Technichem",
     "meta": [
      "24 November 2025",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Establishment of appropriate controls over computer or related systems t o assure that only authorized personnel institute changes in master production and control records or other records (21 CFR 211.68(b)).",
       "tone": "source",
       "mark": [
        87,
        130
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cdl-services-inc-dba-technichem-713877-11242025",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Guangxi Yulin Pharmaceutical Group",
     "meta": [
      "30 September 2025",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).",
       "tone": "source",
       "mark": [
        98,
        141
       ]
      },
      {
       "label": "FDA, next sentence",
       "text": "Your laboratory equipment lacked sufficient controls to prevent and detect deletion or manipulation of your laboratory's electronic raw data.",
       "tone": "context"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/guangxi-yulin-pharmaceutical-group-co-ltd-710422-09302025",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Wisconsin Pharmacal Company",
     "meta": [
      "22 August 2025",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).",
       "tone": "source",
       "mark": [
        98,
        141
       ]
      },
      {
       "label": "FDA, next sentence",
       "text": "Your firm lacked sufficient controls over your liquid chromatography (LC) and gas chromatography (GC) instrument used to test drug products prior to release.",
       "tone": "context"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wisconsin-pharmacal-company-llc-710329-08222025",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Evi Labs",
     "meta": [
      "14 May 2025",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Ensure appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).",
       "tone": "source",
       "mark": [
        76,
        119
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/evi-labs-llc-705846-05142025",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Cosco International",
     "meta": [
      "14 April 2025",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Establishment of appropriate controls of computerized records and access permissions for authorized personnel (21 CFR 211.68(b)).",
       "tone": "source",
       "mark": [
        89,
        109
       ]
      },
      {
       "label": "FDA, next sentence",
       "text": "Your firm’s quality systems are inadequate.",
       "tone": "context"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cosco-international-inc-701209-04142025",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Dyno Manufacturing",
     "meta": [
      "9 April 2025",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Appropriate controls over computer or related systems to assu re that only authorized personnel institute changes in master production and control records, or other records as required by 21 CFR 211.68(b).",
       "tone": "source",
       "mark": [
        70,
        113
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dyno-manufacturing-inc-700785-04092025",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "NWL Netherlands Services",
     "meta": [
      "1 April 2025",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).",
       "tone": "source",
       "mark": [
        98,
        141
       ]
      },
      {
       "label": "FDA, next sentence",
       "text": "Your laboratory equipment used to generate analytical data for finished drug product release lacked restricted access and sufficient controls.",
       "tone": "context"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nwl-netherlands-services-bv-701206-04012025",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "International Laboratories",
     "meta": [
      "10 March 2025",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).",
       "tone": "source",
       "mark": [
        98,
        141
       ]
      },
      {
       "label": "FDA, next sentence",
       "text": "Your laboratory equipment, used to generate analytical data for finished drug product release and stability testing, lacked restricted access and sufficient controls.",
       "tone": "context"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/international-laboratories-corp-698522-03102025",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Annovex Pharma",
     "meta": [
      "5 March 2025",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).",
       "tone": "source",
       "mark": [
        98,
        141
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/annovex-pharma-inc-698115-03052025",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Aspen Pharmacare Holdings",
     "meta": [
      "24 February 2025",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).",
       "tone": "source",
       "mark": [
        98,
        141
       ]
      },
      {
       "label": "FDA, next sentence",
       "text": "Your Production and QU did not review electronic raw data and audit trails to ensure data integrity prior to batch release.",
       "tone": "context"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/aspen-pharmacare-holdings-limited-701671-02242025",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Unexo Lifesciences",
     "meta": [
      "6 November 2024",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).",
       "tone": "source",
       "mark": [
        98,
        141
       ]
      },
      {
       "label": "FDA, next sentence",
       "text": "For example, your QC analyst had the ability to manipulate results, dates, and images of in-house and vendor stamp approvals on component certificate of analyses (COAs) from third-party contract laboratories, including the means to duplicate the stamp approval across multiple COAs for components, such as (b)(4) , lot (b)(4) , lot (b)(4) .",
       "tone": "context"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/unexo-lifesciences-private-limited-688163-11062024",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Outin Futures",
     "meta": [
      "25 September 2024",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).",
       "tone": "source",
       "mark": [
        98,
        141
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/outin-futures-corp-684688-09252024",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "MMC Healthcare",
     "meta": [
      "24 September 2024",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).",
       "tone": "source",
       "mark": [
        98,
        141
       ]
      },
      {
       "label": "FDA, next sentence",
       "text": "Your ultraviolet-visible (UV-Vis) spectrophotometer computer system lacked appropriate controls to assure the integrity of electronic test data, such as an audit trail and defined user access levels.",
       "tone": "context"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/mmc-healthcare-ltd-684644-09242024",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Central Admixture Pharmacy Services",
     "meta": [
      "10 July 2024",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other reco rds (21 CFR 211.68(b)).",
       "tone": "source",
       "mark": [
        98,
        141
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/central-admixture-pharmacy-services-inc-687936-07102024",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Laboratorio Magnachem International",
     "meta": [
      "18 June 2024",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).",
       "tone": "source",
       "mark": [
        98,
        141
       ]
      },
      {
       "label": "FDA, next sentence",
       "text": "Your laboratory equipment used to generate analytical data for finished drug product release lacked restricted access and sufficient controls.",
       "tone": "context"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/laboratorio-magnachem-international-673796-06182024",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Landy International",
     "meta": [
      "12 June 2024",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).",
       "tone": "source",
       "mark": [
        98,
        141
       ]
      },
      {
       "label": "FDA, next sentence",
       "text": "Your stand-alone gas chromatogram (GC) computer system lacked appropriate controls, such as an audit trail and individual log-in access to prevent the deletion of data.",
       "tone": "context"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/landy-international-679066-06122024",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Grupo Quimico SRL",
     "meta": [
      "30 April 2024",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CF R 211.68(b)).",
       "tone": "source",
       "mark": [
        98,
        141
       ]
      },
      {
       "label": "FDA, next sentence",
       "text": "Your firm did not have appropriate controls over your analytical equipment and software to prevent deletion of data and record all modifications to data.",
       "tone": "context"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/grupo-quimico-srl-674010-04302024",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Central Admixture Pharmacy Services",
     "meta": [
      "25 March 2024",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).",
       "tone": "source",
       "mark": [
        98,
        141
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/central-admixture-pharmacy-services-inc-675065-03252024",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "QuVa Pharma",
     "meta": [
      "26 January 2024",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).",
       "tone": "source",
       "mark": [
        98,
        141
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/quva-pharma-inc-675685-01262024",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Brenntag Great Lakes",
     "meta": [
      "26 October 2023",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Appropriate control over computer systems (21 CFR 211.68(b) ).",
       "tone": "source",
       "mark": [
        25,
        41
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/brenntag-great-lakes-llc-660268-10262023",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Omega Packaging",
     "meta": [
      "20 March 2023",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Establishment of appropriate data integrity controls (21 CFR 211.68(b)).",
       "tone": "source",
       "mark": [
        29,
        52
       ]
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/omega-packaging-corp-649122-03202023",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "System Kosmetik Produktionsgesellschaft fur kosmetische Gmbh",
     "meta": [
      "9 September 2022",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).",
       "tone": "source",
       "mark": [
        98,
        141
       ]
      },
      {
       "label": "FDA, next sentence",
       "text": "You failed to have adequate controls in place for your Fourier Transform Infrared Spectrometer (FTIR) system.",
       "tone": "context"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/system-kosmetik-produktionsgesellschaft-fur-kosmetische-gmbh-632727-09092022",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Green Wave Analytical",
     "meta": [
      "19 August 2022",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).",
       "tone": "source",
       "mark": [
        98,
        141
       ]
      },
      {
       "label": "FDA, next sentence",
       "text": "Your f irm lacked sufficient controls over your HPLC data acquisition systems used in the testing of drugs for release.",
       "tone": "context"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/green-wave-analytical-llc-630965-08192022",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Colorful Products",
     "meta": [
      "10 May 2022",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records. (21 CFR 211.68(b)).",
       "tone": "source",
       "mark": [
        98,
        141
       ]
      },
      {
       "label": "FDA, next sentence",
       "text": "Your firm lacked controls to assure the integrity of (b)(4) used in the manufacturing of your drug products.",
       "tone": "context"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/colorful-products-corporation-624415-05102022",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Vi-Jon",
     "meta": [
      "31 March 2022",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in the master production and control records, or other records (21 CFR 211.68(b)).",
       "tone": "source",
       "mark": [
        98,
        141
       ]
      },
      {
       "label": "FDA, next sentence",
       "text": "Your firm failed to implement adequate controls to support the integrity of your electronic data and to ensure that only appropriate individuals had administrative rights.",
       "tone": "context"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/vi-jon-llc-622087-03312022",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Ultra Seal",
     "meta": [
      "14 March 2022",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).",
       "tone": "source",
       "mark": [
        98,
        141
       ]
      },
      {
       "label": "FDA, next sentence",
       "text": "Your firm did not have adequate oversight and control of its electronic data and software systems.",
       "tone": "context"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ultra-seal-corporation-624650-03142022",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Accu Bio-Chem Laboratories",
     "meta": [
      "24 February 2022",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).",
       "tone": "source",
       "mark": [
        98,
        141
       ]
      },
      {
       "label": "FDA, next sentence",
       "text": "The electronic data systems that you use to generate drug product results lack appropriate controls.",
       "tone": "context"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/accu-bio-chem-laboratories-619450-02242022",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Sanitor",
     "meta": [
      "29 November 2021",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and con trol records, or other records (21 CFR 211.68(b)).",
       "tone": "source",
       "mark": [
        98,
        141
       ]
      },
      {
       "label": "FDA, next sentence",
       "text": "Your (b)(4) Fourier Transform Infrared (FTIR) Spectroscopy computerized system did not have appropriate controls in place to prevent deletion of raw laboratory data.",
       "tone": "context"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sanitor-corporation-616232-11292021",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Missouri Analytical Laboratories",
     "meta": [
      "30 September 2021",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to exercise appropriate controls over computer or related sy stems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).",
       "tone": "source",
       "mark": [
        99,
        142
       ]
      },
      {
       "label": "FDA, next sentence",
       "text": "Your firm did not have adequate system security and access control for the (b)(4) system.",
       "tone": "context"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/missouri-analytical-laboratories-inc-615319-09302021",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "Adamson Analytical Laboratories",
     "meta": [
      "17 August 2021",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).",
       "tone": "source",
       "mark": [
        98,
        141
       ]
      },
      {
       "label": "FDA, next sentence",
       "text": "Your firm lacked sufficient controls over your gas chromatography (GC) data acquisition systems used to test drug product before release of analytical data.",
       "tone": "context"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/adamson-analytical-laboratories-inc-614644-08172021",
     "urlLabel": "FDA's letter"
    },
    {
     "title": "BBC Group",
     "meta": [
      "4 August 2021",
      "Drug CGMP warning letter"
     ],
     "quotes": [
      {
       "label": "FDA",
       "text": "Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production an d control records, or other records (21 CFR 211.68(b)).",
       "tone": "source",
       "mark": [
        98,
        141
       ]
      },
      {
       "label": "FDA, next sentence",
       "text": "Your firm manufactures over-the-counter (OTC) drug products, including alcohol-based hand sanitizers [1] .",
       "tone": "context"
      }
     ],
     "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bbc-group-limited-614659-08042021",
     "urlLabel": "FDA's letter"
    }
   ],
   "note": "34 letters, newest first. Every one is about who can change or delete data; none cites the rule's sentence on checking output for accuracy."
  }
 ],
 "download": "Every card is in the {json}; the yearly counts are in the CSV below."
}
